Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Outcomes of HCT and CAR-T recipients after developing COVID-19

Muhammad Bilal Abid • 7 Mar 2022
General CAR-T

Muhammad Bilal Abid, MD, MRCP, Medical College of Wisconsin, Milwaukee, WI, discusses the poor outcomes associated with hematopoietic cell transplantation (HCT) and CAR-T recipients who develop COVID-19. In his discussion, Dr Abid explains that multiple analyses have found high percentages of COVID-19 attributable mortality rates in these patients. Dr Abid then explains some of the reasons why CAR-T recipients have such poor outcomes, including patient-related factors, disease-related factors, and intensity of lymphodepleting chemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Muhammad Bilal Abid

4:00
Younger matched unrelated donor vs. older matched sibling donor for alloSCT in patients with B-ALL
Muhammad Bilal Abid • 11 Dec 2022
4:11
AlloSCT outcomes from younger matched unrelated donor versus older sibling donor for AML
Muhammad Bilal Abid • 11 Dec 2022
3:50
The impact of G-CSF on CAR-T therapy recipients
Muhammad Bilal Abid • 23 Apr 2022
4:44
Optimizing lymphodepletion chemotherapy in CAR-T therapy recipients
Muhammad Bilal Abid • 23 Apr 2022

Related Videos

1:08
Chronological age no longer dictates eligibility for allogeneic transplantation in patients with MDS
Didier Blaise • 4 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
2:44
Do biomarkers exist for predicting response to CAR T-cell therapy?
Marco Ruella • 9 Apr 2024
2:43
Resistance to CAR T-cell therapy
Marco Ruella • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals